UNITED
STATES




SECURITIES
AND EXCHANGE COMMISSION




WASHINGTON, D.C.
20549




FORM
10-K/A







Amendment
No. 1 to Form 10-K






ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE




SECURITIES
EXCHANGE ACT OF 1934




FOR THE FISCAL YEAR
ENDED DECEMBER 31, 2007




Commission File No.
333-142979




TRIPLE A MEDICAL,
INC.





Nevada
            
            20-4846807(State
      or other jurisdiction of incorporation or organization)
            
            (IRS
      Employer Identification No.)







604
Creekview, Ovilla, Texas 75154


(PRINCIPAL
EXECUTIVE OFFICES)




972 /
596-0066


(ISSUER'S TELEPHONE
NUMBER)




Securities
registered under Section 12(b) of the Exchange Act: None




Securities registered under Section
12(g) of the Exchange Act: Common Stock, $0.001 par value




Check whether the issuer is not
required to file reports pursuant to Section 13 or 15 (d) of the Exchange Act.[
]




Check
whether the issuer (1) filed all reports required to be filed by Section 13 or
15(d) of the Exchange Act during the past 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days. Yes [X] No [ ]




Check if there is no disclosure of
delinquent filers in response to Item 405 of Regulation S-B contained in this
form, and no disclosure will be contained, to the best of registrant's
knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-K or any amendment to this Form 10-K.
[X]




Indicate by check mark whether the
registrant is a shell company (as defined in Rule 12b-2 under the Exchange Act).
Yes [X] No [ ]




As of September 30, 2008, the aggregate
market value of the common stock held by non-affiliates based on the closing
sale price of Common Stock was $525,520. For the purposes of the foregoing
calculation only, all directors, executive officers, related parties and holders
of more than 10% of the issued and outstanding common stock of the registrant
have been deemed affiliates.




As of
September 30, 2008, the issuer had 14,050,500 shares of common stock
outstanding.




Documents
incorporated by reference: none




Transitional
Small Business Disclosure Format (check one): Yes [  ] No [X]






















Amendment
No. 1 to the Annual Report on Form 10-K




For the
Year Ended December 31, 2007







EXPLANATORY
NOTE





This Form
10-K/A is being filed by Triple A Medical, Inc., to amend the Company’s Annual
Report on Form 10-K for the year ended December 31, 2007 that was originally
filed with the Securities and Exchange Commission on April 10,
2008.





This Form
10-K/A amends and restates, pursuant to ITEM 307 of Regulation S-K, Disclosure
of Controls and Procedures, and ITEM 601(b)(31) of Regulation S-B, the Exhibit
31.1, Certification of the Principal Executive Officer and Exhibit 31.2,
Certification Principal Financial Officer, which adds the introductory language
of paragraph 4 and the language paragraph 4(b).





In
addition, as part of the 10-K/A, the Amendment also includes the report signed
on behalf of the registrant by our principal executive officer, our principal
financial officer and our sole director.





Except
with respect to the above changes, this Amendment does not modify or update any
other disclosures set forth in the Original or First Amended
filing.














2




TABLE
OF CONTENTS
  PagePART IFinancial
      Statements
              
              F-1ITEM
      1.
              Description
      of Business
              
              13ITEM
      2.
              Description
      of Property
              
              15ITEM
      3.
              Legal
      Proceedings
              
              15ITEM
      4.
              Submission
      of Matters to a Vote of Security Holders
              
              15PART IIITEM
      5.
              Market
      for Registrant’s Common Equity And Related Stockholders
      Matters
              
              16ITEM
      6.
              Selected
      Financial Data.
              
              16ITEM
      7.
              Management’s
      Discussion and Analysis of Financial Condition and Results of
      Operation.
              
              16ITEM
      7A.
              Quantitative
      and Qualitative Disclosures About Market Risk.
              
              17ITEM
      8.
              Financial
      Statements and Supplementary Data.
              
              17ITEM
      9.
              Changes
      in and Disagreements with Accountants on Accounting and Financial
      Disclosure.
              
              18ITEM
      9A.
              Controls
      and Procedures.
              
              18ITEM
      9B.
              Other
      Information.
              
              19PART IIIITEM
      10.
              Directors,
      Executive Officers and Corporate Governance.
              
              20ITEM
      11.
              Executive
      Compensation.
              
              20ITEM
      12.
              Security
      Ownership of Certain Beneficial Owners and Management and Related
      Stockholder Matters
              
              20ITEM
      13.
              Certain
      Relationships and Related Transactions, and Director
      Independence
              
              22ITEM
      14.
              Principal
      Accounting Fees and Services.
              
              22PART IVITEM
      15.
              Exhibits
      and Financial Statement Schedules.
              
              23EXHIBIT
      INDEX
              
              23Exhibit 31.1
              Certification
      of Chief Executive Officer, pursuant to Rule 13a-14(a) of the Exchange
      Act, as enacted by Section 302 of the Sarbanes-Oxley Act of
      2002.Exhibit 31.2
              Certification
      of Chief Financial Officer, pursuant to Rule 13a-14(a) of the Exchange
      Act, as enacted by Section 302 of the Sarbanes-Oxley Act of
      2002.Exhibit 32.1
              Certification
      of Chief Executive Officer and Chief Financial Officer, pursuant to 18
      United States Code Section 1350, as enacted by Section 906 of the
      Sarbanes-Oxley Act of 2002.SIGNATURES
              
              24
   
 
  3
 
  
  
  REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  
 
 To the
Board of Directors
 Triple A
Medical, Inc.
 Ovilla,
Texas
 
 We have
audited the accompanying consolidated balance sheets of Triple A Medical, Inc. ,
as of December 31, 2007 and 2006, and the related consolidated statements of
operations, changes in stockholders' equity, and cash flows for the years then
ended. These consolidated financial statements are the responsibility of the
management of Triple A Medical, Inc.  Our responsibility is to express
an opinion on these consolidated financial statements based on our
audits.
 
 We
conducted our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan
and perform an audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. Triple A Medical, Inc is not
required to have, nor were we engaged to perform, an audit of its internal
control over financial reporting. Our audits included consideration of internal
control over financial reporting as a basis for designing audit procedures that
are appropriate in the circumstances, but not for the purpose of expressing an
opinion on the effectiveness of Triple A Medical, Inc’s internal control over
financial reporting. Accordingly, we express no such opinion. An audit also
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, as well as evaluating the
overall financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.
 
 In our
opinion, the financial statements referred to above present fairly, in all
material respects, the financial position of Triple A Medical, Inc. as of
December 31, 2007 and 2006, and the results of its operations and its cash flows
for the periods described in conformity with accounting principles generally
accepted in the United States of America.
 
 The
accompanying consolidated financial statements have been prepared assuming that
the Company will continue as a going concern. As discussed in Note 2 to the
financial statements, the Company has suffered recurring losses from operations
and has recurring deficits in cash flows form operating activities, which raises
substantial doubt about its ability to continue as a going concern. Management's
plans regarding these matters also are described in Note 2. The financial
statements do not include any adjustments that might result from the outcome of
this uncertainty.
 
 /s/  Malone &
Bailey, PC
 MALONE
& BAILEY, PC
 www.malone-bailey.com
 Houston,
Texas
 
 March 31,
2008
 
 
 
 
 
 
 
 
 
 
  F-1
  TRIPLE
      A MEDICAL, INC.Consolidated
      Balance SheetsDecember
      31, 2007 and 2006ASSETS
              
              2007
              
              
              2006Current
      AssetsCash
      and Cash Equivalents
              
              $
              270,906
              
              
              $
              265,728Other
      receivables
              
              
              1,100
              
              
              
              -Prepaid
      Expenses
              
              
              29,363
              
              
              
              -Total
      Current Assets
              
              
              301,369
              
              
              
              265,728Computer
      Equipment, net
              
              
              23,270
              
              
              
              -Developed
      Software, net
              
              
              362,549
              
              
              
              379,322TOTAL
      ASSETS
              
              $
              687,188
              
              
              $
              645,050LIABILITIES
      AND STOCKHOLDERS' EQUITYCurrent
      LiabilitiesAccounts
      Payable and Accrued Expenses
              
              $
              67,756
              
              
              $
              32,996Total
      Current Liabilities
              
              
              67,756
              
              
              
              32,996Commitments
      and contingencies
              
              
              -
              
              
              
              -Stockholders'
      EquityPreferred
      stock, $0.01 par value, 20,000,000 authorized,-0-  issued
      and outstanding
              
              
              -
              
              
              
              -Common
      Stock, $.001 par value, 50,000,000 shares authorized,13,744,000
      and 13,500,00 shares issued and outstanding, respectively
              
              
              13,744
              
              
              
              13,500Additional
      Paid-In Capital
              
              
              1,258,756
              
              
              
              753,000Accumulated  Deficit
              
              
              (653,068
              )
              
              
              (154,446
              )Total
      Stockholders' Equity
              
              
              619,432
              
              
              
              612,054TOTAL
      LIABILITIES AND STOCKHOLDERS' EQUITY
              
              $
              687,188
              
              
              $
              645,050See
      accompanying summary of accounting policies and notes to consolidated
      financial statements.
  F-2
  TRIPLE A MEDICAL, INC.Consolidated
      Statements of OperationsYears
      Ended December 31, 2007 and 20062007
              
              
              2006REVENUE
              
              $
              207,443
              
              
              $
              -OPERATING
      EXPENSESDepreciation
      and amortization
              
              
              21,389
              
              
              
              -Selling,
      General & Administrative:
              
              
              434,765
              
              
              
              11,498Software
      Development Costs
              
              
              255,437
              
              
              
              132,653TOTAL
      OPERATING EXPENSES
              
              
              711,591
              
              
              
              144,151NET
      LOSS FROM OPERATIONS
              
              
              (504,148
              )
              
              
              (144,151
              )OTHER
      INCOMEInterest
      income
              
              
              5,526
              
              
              
              3,205NET
      LOSS
              
              $
              (498,622
              )
              
              $
              (140,946
              )Basic
      and diluted weighted average shares outstanding
              
              
              13,535,751
              
              
              
              13,500,000Basic
      and diluted net loss per share
              
              $
              (0.04
              )
              
              $
              (0.01
              )See
      accompanying summary of accounting policies and notes to consolidated
      financial statements.
  F-3
  
 
 TRIPLE A MEDICAL, INC.Consolidted
      Statements of Stockholders' EquityYears
      Ended December 31, 2007 and 2006Common
      Stock
              
              
              Paid-In
              
              
              AccumulatedShares
              
              
              Amount
              
              
              Capital
              
              
              Deficit
              
              
              TotalsBalance
      at December 31, 2005
              
              
              13,500,000
              
              
              $
              13,500
              
              
              $
              -
              
              
              $
              (13,500
              )
              
              
              -Imputed
      rent
              
              
              
              
              
              
              
              
              
              
              8,000
              
              
              
              
              
              
              
              8,000Contributed
      capital
              
              
              
              
              
              
              
              
              
              
              745,000
              
              
              
              
              
              
              
              745,000Net
      Loss
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              (140,946
              )
              
              
              (140,946
              )Balance
      at December 31, 2006
              
              
              13,500,000
              
              
              
              13,500
              
              
              
              753,000
              
              
              
              (154,446
              )
              
              
              612,054Contributed
      capital
              
              
              
              
              
              
              
              
              
              
              376,000
              
              
              
              
              
              
              
              376,000Imputed
      rent
              
              
              
              
              
              
              
              
              
              
              8,000
              
              
              
              
              
              
              
              8,000Cash
      received for stock
              
              
              244,000
              
              
              
              244
              
              
              
              121,756
              
              
              
              
              
              
              
              122,000Net
      Loss
              
              
              
              
              
              
              
              
              
              
              
              
              
              
              (498,622
              )
              
              
              (498,622
              )Balance
      at December 31, 2007
              
              
              13,744,000
              
              
              $
              13,744
              
              
              $
              1,258,756
              
              
              $
              (653,068
              )
              
              $
              619,432See
      accompanying summary of accounting policies and notes to consolidated
      financial statements.
     F-4
 
  TRIPLE A MEDICAL, INC.Consolidated
      Statements of Cash FlowsYears
      Ended December 31, 2007 and 20062007
                
                
                2006CASH
      FLOWS FROM OPERATING ACTIVITIESNet
      Loss
                
                $
                (498,622
                )
                
                $
                (140,946
                )Adjustments
      to reconcile net income to net cashprovided
      by operating activities:Depreciation
      and amortization
                
                
                21,389
                
                
                
                -Imputed
      rent
                
                
                8,000
                
                
                
                8,000Accounts
      receivable - employee
                
                
                (1,100
                )
                
                
                -Prepaid
      expenses
                
                
                (29,363
                )
                
                
                -Change
      in Accounts Payable and Accrued Expenses
                
                
                34,760
                
                
                
                32,996Net
      Cash Used in Operating Activities
                
                
                (464,936
                )
                
                
                (99,950
                )CASH
      FLOWS FROM INVESTING ACTIVITIESSoftware
      development costs
                
                
                -
                
                
                
                (379,322
                )Purchase
      of fixed assets
                
                
                (27,886
                )
                
                
                -Net
      Cash Used in Investing Activities
                
                
                (27,886
                )
                
                
                (379,322
                )CASH
      FLOWS FROM FINANCING ACTIVITIESContributed
      capital
                
                
                376,000
                
                
                
                745,000Proceeds
      from Sale of Stock
                
                
                122,000
                
                
                
                -Net
      Cash Provided by Financing Activities
                
                
                498,000
                
                
                
                745,000NET
      INCREASE IN CASH AND CASH EQUIVALENTS
                
                
                5,178
                
                
                
                265,728CASH
      AND CASH EQUIVALENTS AT BEGINNING OF YEAR
                
                
                265,728
                
                
                
                -CASH
      AND CASH EQUIVALENTS AT END OF YEAR
                
                $
                270,906
                
                
                $
                265,728SUPPLEMENTAL
      DISCLOSURESInterest
      paid
                
                $
                -
                
                
                $
                -Income
      taxes paid
                
                $
                -
                
                
                $
                -See
      accompanying summary of accounting policies and notes to consolidated
      financial statements.
 
    F-5
   
 TRIPLE
A MEDICAL, INC.
 Notes to
the Consolidated Financial Statements
 December
31, 2007 and 2006
 
 
 NOTE 1 –
NATURE OF ACTIVITIES AND SIGNIFICANT ACCOUNTING POLICIES
 
 Nature of Activities,
History and Organization:
 
 Triple A
Medical, Inc. (Triple A), through its wholly owned subsidiary Triple A Software,
Inc. (TAS), has developed and is in the process of selling and distributing a
proprietary software developed for use as an electronic medical record by
orthopedic surgeons. Triple A is located in Ovilla, Texas and was incorporated
on December 27, 2006 in Nevada.
 
 Triple A
is the parent company of TAS, a Texas corporation. TAS was established in 2005
and since that time has been working to develop software. The software being
developed is designed as an easy to use, interactive software with customization
that can be made as it is used.
 
 On
December 29, 2006, Triple A issued 13,500,000 shares of common stock in exchange
for a 100% equity interest in TAS. As a result of the share exchange, TAS became
the wholly owned subsidiary of Triple A. The share exchange was treated as a
recapitalization of TAS. The financial statements have been prepared as if TAS
had always been the reporting company and then on the share exchange date, had
changed its name and reorganized its capital stock.
 
 Significant Accounting
Policies
 
 Use of
Estimates
 
 The
preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions that
affect certain reported amounts and disclosures.  Accordingly, actual
results could differ from those estimates.
 
 Cash and Cash
Equivalents
 
 All
highly liquid investments with original maturities of three months or less are
stated at cost which approximates market value.
 
 Property and
Equipment
 
 Property
and equipment are carried at the cost of acquisition or construction and
depreciated over the estimated useful lives of the assets. Costs associated with
repair and maintenance are expensed as incurred. Costs associated with
improvements which extend the life, increase the capacity or improve the
efficiency of our property and equipment are capitalized and depreciated over
the remaining life of the related asset. Gains and losses on dispositions of
equipment are reflected in operations. Depreciation is provided using the
straight-line method over the estimated useful lives of the assets, which is 3
years.
    F-6
  
 Software Development
Costs
 
 Triple A
follows Statement of Financial Accounting Standards 86, “Accounting for the
costs of computer software to Be Sold, Leased, or Otherwise
Marketed”.  In accordance with SFAS 86, internal costs incurred to
create computer software are charged to expense when incurred until
technological feasibility has been established for the product. Technological
feasibility is established upon completion of a detailed program design or, in
its absence, completion of a working model. After technological feasibility is
established, the costs of coding and testing and other costs of producing
product masters are capitalized. Cost capitalization ceases when the product is
available for general release to customers.
 
 Capitalized
software costs are amortized on a product-by-product basis, starting when the
product is available for general release to customers. Annual amortization is
the greater of straight-line over the product's estimated useful life or the
percent of the product's current-year revenues as compared to the product's
anticipated future revenues.
 
 Capitalized
software costs are evaluated for impairment on a product-by-product basis by a
comparison of the unamortized capitalized costs to the product's net realizable
value. The amount by which the unamortized capitalized costs exceed the net
realizable value is recognized as an impairment charge.
 
 Revenue
Recognition
 
 Triple A
recognizes revenue when software is sold, delivery has occurred, the sales price
is fixed or determinable and collectibility is probable. Triple A recognizes
revenue from installation and other services as the services are performed.
 
 Income
Taxes
 
 Income
taxes are computed using the asset and liability method.  Under the asset
and liability method, deferred income tax assets and liabilities are determined
based on the differences between the financial reporting and tax bases of assets
and liabilities and are measured using the currently enacted tax rates and laws.
 A valuation allowance is provided for the amount of deferred tax assets
that, based on available evidence, are not expected to be realized.
 
 Earnings (Loss) per
Share
 
 Earnings
(loss) per share (basic) is calculated by dividing the net income (loss) by the
weighted average number of common shares outstanding for the period
covered.  As Triple A has no potentially dilutive securities, fully
diluted earnings (loss) per share is identical to earnings (loss) per share
(basic).
 
 NOTE 2 - GOING
CONCERN
 
 Triple A
's financial statements have been presented on the basis that it is a going
concern, which contemplates the realization of assets and the satisfaction of
liabilities in the normal course of business.  Triple A has suffered
recurring losses since inception and accumulated a deficit of $653,068 as of
December 31, 2007. Additionally, Triple A has incurred recurring deficits in
cash flows from operating activities.
     F-7
   Triple A 's ability to continue as a
going concern is dependent upon its ability to complete the development of its
developed software product with existing sources of capital, to successfully
market and implement its developed software product and to achieve profitable
operations.  The accompanying financial statements do not include any
adjustments that might result from the outcome of these
uncertainties.
 
 NOTE 3 -
CONCENTRATIONS
 
 Triple A
maintains demand deposit accounts which at times exceed FDIC insurance
limitations of $100,000 per account. Balances on deposit at financial
institutions as of December 31, 2007 in excess of FDIC deposit insurance amounts
were $170,906.
 
 NOTE 4 - PROPERTY AND
EQUIPMENT
 
 Property
and equipment consisted of the following at December 31, 2007 and
2006:
 
 
 Description
              Life
              
              2007
                Amount
              
              
              2006
                AmountComputer
      equipment
              3
      years
              
              $
              24,639
              
              
              $
              0Accumulated
      depreciation
              
              
              
              (1,369
              )
              
              
              0$
              23,270
              
              
              $
              0
 
 Depreciation
expense totaled $1,369 and $0 in 2007 and 2006, respectively.
 
 
 NOTE 5 – CAPITALIZED
SOFTWARE DEVELOPMENT COSTS
 
 Capitalized
software development costs at December 31, 2007 and 2006 consist of the
following:
 
 2007
              
              
              2006Software
              
              $
              382,569
              
              
              $
              379,322Less:
      accumulated amortization
              
              
              (20,020
              )
              
              
              (0
              )$
              362,549
              
              
              $
              379,322
 
 
 Amortization
expense totaled $20,020 and $0 in 2007 and 2006, respectively
 
 $132,653
of software development costs was expensed during 2006 and $255,437 in
2007.
    F-8
 
  NOTE 6 – INCOME
TAXES
 
 Deferred
tax assets at December 31, 2007 and 2006 consisted of the
following:
 
 Year
      ended December 31, 2007
              
              
              Year
      ended December 31, 2006Net
      operating loss carryforward
              
              $
              222,043
              
              
              $
              52,512Less:
      valuation allowance
              
              
              (222,043
              )
              
              
              (52,512
              )Net
      deferred tax asset
              
              
              -
              
              
              
              -
 
 The net
deferred tax asset generated by the loss carry-forward has been fully reserved.
 The cumulative net operating loss carry-forward is approximately $653,000
at December 31, 2007, and will expire in the years 2024 through
2027.
 
 The
difference in the income tax benefit not shown in the consolidated statements of
operations and the amount at
that  would  result  if  the U.S.
Federal statutory
rate  of  34%  were  applied to pre-tax
loss for 2007 and 2006 is attributable to the valuation allowance.
 
 The
realization of deferred tax benefits is contingent upon future
earnings.
 
 
 NOTE 7 – RELATED PARTY
TRANSACTIONS
 
 In order
to fund the development of the software, Triple A entered into  an
‘Investment and Net Revenue Agreement’ with Phoenix Ortho, LLC (ORTHO), an
entity controlled by a relative of the President of Triple A. In connection with
this agreement ORTHO provided Triple A $745,000 during 2006 and $396,000 in
2007. This cash is reflected as additional paid-in capital as of December 31,
2006 and 2007. In exchange for this contributed capital, Triple A provided ORTHO
with an income participation interest in its operations. The terms of this
agreement require Triple A to pay ORTHO 32.60% of the net income generated by
the business in the immediately preceding month.
 
 In
addition, office space has been contributed by related parties since April 2006
rent-free.  $8,000 per year of expense has been imputed related to
this office space.
 
 NOTE 8 – MAJOR
CUSTOMERS
 
 Revenues
had two customers that consisted of 93% of revenues for 2007. There were no
major customers in 2006.
 
 NOTE 9 – SUBSEQUENT
EVENTS
 
 In 2007
the Company had filed a Form SB-1 with the U.S. Securities & Exchange
Commission which became effective in July 2007. Under the Form SB-1, the Company
filed to offer a minimum of $75,000 and a maximum of $500,000. In March 2008,
the Company  raised a total amount of $258,750 of which 136,750 was
raised after December 31, 2007.
 
  F-9
  PART I.
 
 ITEM
1.                      DESCRIPTION OF
BUSINESS
 
 This
report contains forward looking statements within the meaning of Section 27A of
the Securities Act of 1933, as amended and Section 21E of the Securities
Exchange Act of 1934, as amended. The Company’s actual results could differ
materially from those set forth on the forward looking statements as a result of
the risks set forth in the Company’s filings with the Securities and Exchange
Commission, general economic conditions, and changes in the assumptions used in
making such forward looking statements.
 
 General
 
 The
company was founded to create electronic healthcare software
applications.  The initial development is an Electronic Health Record
(EHR), specifically designed to meet the needs of orthopedic physicians. For the
past 4 years, our President has worked directly with dozens of orthopedic
physicians in more than 40 states. He has reviewed orthopedic clinical research
and extensively surveyed reference materials. Based upon the research, Mr.
McCune created a database with a graphical interface to assist orthopedic
physicians with the documentation of the patient encounter.
 
 The
Market
 
 Phoenix
Ortho is participating in an $18 billion market for Electronic Health Records
(EHR). The Orthopedics market approaches $2 billion. There are more than 20,500
board certified orthopedists and 12,872 orthopedic group practices. Research
indicates that this market is less than 10% penetrated.  Recent
surveys indicate that 58% of medical practices are looking at purchasing an EHR
in the next 2 years. In 2005 the average orthopedic EHR sale was $171,000. (2001
AAOS Census, 2004 MGMA Survey) Recent growth rate in new sales has averaged
about 30%. We expected this growth rate will accelerate sharply over the next
two years.
 
 Keys
to Success
 
 Focus: We believe focus is the
essential ingredient to successful EHR development and deployment. Phoenix Ortho
is unique in our extensive experience and singular focus on orthopedics. By
focusing on one specialty, we can avoid the wholesale generalities that have
plagued EHR vendors and frustrated their orthopedic clients. Phoenix Ortho
understands the unique requirements of orthopedic physicians. Focus promotes the
creation of relevant content and specialty specific application functionality.
Content relevance is a significant factor in physician adoption.
 
 In
November of 2005, we began the development of a new
orthopedic EHR. The new project was focused on resolving the key problems that
have historically posed barriers to adoption, successful implementation and
client satisfaction. These obstacles can be grouped together in four categories;
Product Functionality, Product Implementation, Product Support, Product
Acquisition Cost.
 
 Product Functionality:The
software will establishnew standards for ease
of use, efficiency, stability and availability facilitating end user adoption.
The software is designed and scaled specifically for the pen tablet environment.
We believe the pen tablet is the device of choice for EHR end users. Our
development will utilize input tools such as sliders, combo boxes, role over
images and other custom designed tools to provide a truly keyboard free
interface. Other tablet input options such as “Pen and Ink” and “Voice to Text”
will be available as needed to capture representative content. The ODClient will
improve stability, performance and availability by utilizing .NET automatic
versioning and auto recovery from deadlock errors and memory leaks. Advanced
compilation and caching techniques substantially lower CPU utilization. The
ODClient (smart client) will support both disconnected and low bandwidth clients
supporting end user mobility and minimizing the frustration of “Systems
down”.
    13
 
 Product Implementation: We
have developed an orthopedic, client focused implementation methodology
we call the “AAA” implementation plan. This plan focuses on the three critical
aspects of implementation; Assessment, Adoption and Adaptation. All
implementations will begin with Assessment. During the assessment phase the
unique needs of the end users are identified. Each user is profiled to determine
their needs and potential road blocks to success. The physicians are identified
as Champions, Contenders or Challengers. An implementation strategy is designed
around these “Adoption Profiles”.  The Champions are the eager
adopters and should be the first users. The Contenders are frequently
indifferent but, usually agreeable adopters.  The Challengers
represent approximately 30% of the physicians who will resist implementation for
a variety of reasons. Sometimes they feel they are too technology challenged and
fearful, some are too busy and may fear loss of revenue by adoption, while
others are just resistant to anything new. When these objections are clearly
understood, “Adaptation” can take place and in most cases mitigate the
Challengers objection(s). Adaptation is the process of introducing (training)
the end users to the application “Best Practices”. It also takes into account
the “Profile” of the end user to create a “Best Practices” by provider (See
Challengers above).
 
 Product Support:The ODClient
on the .NET framework makes it easier than ever to update and deploy new
applications. Thanks to intelligent, one touch updates and intelligent support
client PCs can be updated by copying the application to the target
directory.  Client PCs may be updated automatically with no
interruption or the may be updated on demand.
 
 Product Acquisition Cost:Wewill
provide alternative acquisition models to help overcome purchase resistance due
to capital costs. Although we will make the EHR software available on the
traditional for purchase basis, through our innovative 3-Tier ODClient
architecture we will also offer a service based model. Our customers will be
able to utilize the full function and features of the EHR software for an
affordable monthly service charge.
 
 Utilizing
their extensive experience and knowledge of orthopedics, coupled with state of
the art rapid development tools, we  believe these obstacles can be
overcome and their goals are achievable. The recent completion of their fully
functional prototype, suggests that their development strategies are on
track.
 
 Technology
Overview
 
 For many
technologists and software developers, 2006 is a “watershed year.” With the
official release of Visual Studio 2005, providing a seamless integration between
C#, the .Net Framework 2.0 and SQL Server 2005, a new paradigm for software
development has arrived. According to Bill Gates “the transition to .NET is as
dramatic as the move from MS-DOS to Windows.”  The emergence of these
companion technologies has created an opportunity for rapid development,
application flexibility, architectural mobility, simplified deployment and
support/updates that did not exist prior to November 2005.
 
 We are
positioned to take full advantage of this shifting technological paradigm. The
software will be the first orthopedic EHR to be developed utilizing innovative
3-Tier architecture on SQL 2005, the .NET framework, C#, Visual Studio 2005 and
the Microsoft Enterprise Library.
     14
 
 Implementation
of 3-Tier Architecture
 
 ODClient:Combines the best of
traditional rich client functionality with the ease of thin client deployment
and maintenance. ODClient raises the standard by adding support for mobile,
offline or low bandwidth users with intelligent connection management (data
caching and batch requests). Even fully connected clients will see performance
and stability benefits. ODClient will reduce management costs by avoiding the
complexities and “application fragility” of traditional rich client deployments
(shared code, registered components, and DLLs in a common folder). ODClient will
utilize a seamless, simplified, predictable “no touch deployment”. Updates may
occur in the background or on demand. Tools: Visual C# 2005, Microsoft Office
2003, XML underlying structure.
 
 Application Server Tier:Business-objects that implement the business rules reside here. This tier
isolates the data from direct access by the clients. Tools: .Net Framework 2.0,
Microsoft Enterprise Library.
 
 Data Server Tier: This tier is
responsible for data storage. SQL Server 2005 with .NET integration is the
database of choice. However, the 3-Tier architecture supports application
portability and database independence. Tools: SQL Server 2005, T-SQL, CLR
Execution Environment, .Net Code Integration, Business Intelligence, Indexed,
Full Text Search
 
 Mission
 
 We will
develop, document and market EHR solutions that are efficient, intuitive, easy
to use, and promote physician acceptance.  This software will reduce
the cost and risks associated with manual paper based systems. This will in turn
improve the quality of care by more completely documenting patient care,
eliminating common errors and tracking relevant procedures, events and outcomes.
The EHR will provide an excellent ROI to the physician by reducing costs and
enhancing revenues do to improved documentation and optimal billable code
levels.
 
 Conclusion
 
 The
orthopedic EHR market is emerging rapidly with nearly $2 billion in potential
sales. We believe that our software is uniquely positioned to fill a substantial
void in the orthopedic vertical market for EHR.Our extensive orthopedic
experience, our singular focus, our dedicated, proactive approach to training,
implementation and support, coupled with our utilization of state of the art
development tools will distinguish us from every alternative EHR in the
orthopedic vertical market space. The result will be a uniquely relevant
orthopedic encounter management solution that is efficient, intuitive, easy to
use, and promotes physician acceptance. We expect this EHR to be well received,
quickly adopted, and widely endorsed by the orthopedic community.
 
  ITEM
2.                      DESCRIPTION
OF PROPERTY
 
 Our
corporate facilities are located in a 1,200 sf office facility at 604 Creekview,
Ovilla, Texas 75154. The space is being contributed to the company until it has
sufficient revenues to commit to a permanent location.
 
 ITEM
3.                      LEGAL
PROCEEDINGS
 
 We are
not involved in any legal proceedings at this time.
 
 ITEM
4.                      SUBMISSION
OF MATTERS TO A VOTE OF SECURITY HOLDERS
 
 The
registrant did not submit any matters to its security holders for a
vote.
 
  15
  
 PART
II
 
 ITEM
      5.
              MARKET
      FOR REGISTRANT’S COMMON EQUITY AND RELATED STOCKHOLDERS
      MATTERS
 
 The
Common Stock was not quoted on any exchange or quoted price medium. Subsequent
to year end, the Company started trading on the OTCBB under the ticker symbol
TAAA.
 
 Shareholders
 As of
December 31, 2007, there were 139 record holders of the Common
Stock.
 
 Dividends
 The
Company has not paid dividends on any class of common equity since formation and
the Company does not anticipate paying any dividends on its outstanding common
stock in the foreseeable future.
 
 Warrants
 The
Company has no warrants outstanding.
 
 
 ITEM
6.                      SELECTED
FINANCIAL DATA
 
 Not
required
 
 
 ITEM
7.                      MANAGEMENT’S
DISCUSSION AND ANALYSIS OR PLAN OF OPERATION
 
 Results
for the fiscal year ended December 31, 2007
 
 At the
end of the first quarter of 2007, our software became operational and we started
marketing it by attending trade shows, print advertising and brochures and
personal contacts.  In August we had our first sale and installation
of the software which took us out of the development stage and into the
operating phase of our business. Our sales leads continue to be followed up on
as we receive them from our own efforts by attendance at trade shows and from
referrals from our industry cross marketing agreements.
 
 REVENUE.  Revenue
for the year ended December 31, 2007 was $207,443 compared to zero revenues in
2006 since 2007 was our first year where we had sales of our software; in 2006
we were still developing our software.
 
 EXPENSES.
Total expenses the twelve months ended December 31, 2007 was $711,591 compared
to $144,151 for the year of 2006. In 2007, the three main components of that
expense were software development costs, depreciation and amortization, and
general and administrative expenses. Software development costs are the amounts
expended on our software after it reached the point of being operational. These
amounts for the twelve months ended December 31, 2007 were $255,437 compared to
$132,653 for the same period in 2006.
    16
 
 We had no
depreciation or amortization in 2006 but recorded $21,389 in 2007.
 
 In 2007,
we had selling, general and administrative expenses of $434,765 compared with
$11,498 in 2006. The significant increase is due to our change from a company
that was just developing software to a company that had a software product and
was marketing and installing it. In order to do this, we had to incur costs for
administration, service and support.
 
 OTHER
INCOME . We had interest income of $5,526 in 2007 compared with $3,205 in 2006.
The increase was due to the greater cash balances the company had during the
year.
 
 NET LOSS.
Net loss for the year ended December 31, 2007 was $498,627 compared with a loss
of $140,946 for the year of 2006. The losses in both years was due to our
company developing software and only started selling in the last part of
2007.
 
 LIQUIDITY
AND CAPITAL RESOURCES. Our cash balance at December 31, 2007 was $270,906. We
filed a Form SB-1 in 2007 and when we closed the offering in March 2008, we had
raised a total of $258,750. Our sales efforts are materializing into sales and
with the cash we have in the bank and the revenue we are starting to see from
sales, we believe we have enough liquidity to carry us to the point where ales
of our software provide enough cash flow to internally fund our
operations.
 
 Employees
 
 As of
December 31, 2007, the Company had three employees.
 
 
 ITEM
7A.                   QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
 Not
applicable
 
 
 ITEM
8.                      FINANCIAL
STATEMENTS AND SUPPLEMENTARY DATA
 
 Incorporated
in this filing are the following financial statements:
 
 Report of
Independent Registered Public Accounting Firm
 Consolidated
Balance Sheets at December 31, 2007 and 2006
 Consolidated
Statements of Operations for the years ended December 31, 2007 and
2006
 Consolidated
Statements of Stockholders’ Equity for the years ended December 31, 2007 and
2006
 Consolidated
Statements of Cash Flows for the years ended December 31, 2007 and
2006
 Notes to
the Financial Statements
    17
   ITEM
9.                      CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE
 
 We have
retained Malone & Bailey, PC as our registered independent public accounting
firm. We have
 had no
disagreements with them on accounting and disclosure issues.
 
 
 ITEM
9A.                  CONTROLS
AND PROCEDURES
 
 Evaluation of Disclosure
Controls and Procedures
 
 Disclosure controls and procedures
include, without limitation, controls and procedures designed to ensure that
information required to be disclosed by an issuer in the reports that it files
or submits under the Securities Exchange Act of 1934, as amended (the "Act") is
accumulated and communicated to the issuer's management, including its principal
executive and principal financial officers, or persons performing similar
functions, as appropriate to allow timely decisions regarding required
disclosure. It should be noted that the design of any system of controls is
based in part upon certain assumptions about the likelihood of future events,
and there can be no assurance that any design will succeed in achieving its
stated goals under all potential future conditions, regardless of how
remote.  As of the end of the period covered by this Annual Report, we
carried out an evaluation, under the supervision and with the participation of
our President, also serving as our Chief Financial Officer, of the effectiveness
of the design and operation of our disclosure controls and procedures. 
Based on this evaluation, our President has concluded that the Company’s
disclosure controls and procedures are not effective because of the
identification of a material weakness in our internal control over financial
reporting which is identified below, which we view as an integral part of our
disclosure controls and procedures.
  Changes in Internal Controls
over Financial Reporting
 
 We have
not yet made any changes in our internal controls over financial reporting that
occurred during the period covered by this report on Form 10-K that has
materially affected, or is reasonably likely to materially affect, our
internal control over financial reporting.
  Management’s Annual Report
on Internal Control Over Financial Reporting
 
 Our management is responsible for
establishing and maintaining adequate internal control over financial reporting,
as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange
Act. Our internal control system was designed to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of
financial statements for external purposes, in accordance with generally
accepted accounting principles. Because of inherent limitations, a system of
internal control over financial reporting may not prevent or detect
misstatements. Also, projections of any evaluation of effectiveness to future
periods are subject to the risk that controls may become inadequate due to
change in conditions, or that the degree of compliance with the policies or
procedures may deteriorate.
    18
   Our
management conducted an evaluation of the effectiveness of our internal control
over financial reporting using the criteria set forth by the Committee of
Sponsoring Organizations of the Treadway Commission (COSO) in Internal
Control—Integrated Framework. Based on its evaluation, our management concluded
that there is a material weakness in our internal control over financial
reporting. A material weakness is a deficiency, or a combination of control
deficiencies, in internal control over financial reporting such that there is a
reasonable possibility that a material misstatement of the Company’s annual or
interim financial statements will not be prevented or detected on a timely
basis.
  The
material weakness relates to the lack of segregation of duties in financial
reporting, as our financial reporting and all accounting functions are performed
by external accountants who may not always get full information and therefore
something is not recorded appropriately.  Our President does not possess
accounting expertise and our company does not have an audit committee. 
This weakness is due to the company’s lack of working capital to hire additional
staff.  To remedy this material weakness, we intend to engage another
accountant to assist with financial reporting as soon as our finances will
allow.
  This
annual report does not include an attestation report of the Company’s registered
public accounting firm regarding internal control over financial
reporting.  Management’s report was not subject to the attestation by the
Company’s registered public accounting firm pursuant to temporary rules of the
SEC that permit the Company to provide only management’s report in this annual
report.
  The
Company’s management carried out an assessment of the effectiveness of the
Company’s internal control over financial reporting as of December 31, 2007. The
Company’s management based its evaluation on criteria set forth in the framework
in Internal Control—Integrated Framework issued by the Committee of Sponsoring
Organizations of theTreadway Commission. Based on that assessment, management
has concluded that the Company’s internal control over financial reporting was
not effective as of December 31, 2007.
 
 
 ITEM
9B.                      OTHER
INFORMATION
 
 The
Registrant filed Form 8-K on December 18, 2007 to announced that in accordance
with its Form SB-1 which became effective on July 6, 2007, we raised at least
our minimum amount by the date of the end of the offering.
  19
  PART
III
 
 ITEM
10.                      DIRECTORS, EXECUTIVE OFFICERS AND
CORPORATE GOVERNANCE
 
 The
directors and officers of the company, their ages and principal positions are as
follows:
 
  P.
      Morgan McCune
                29
                Director,
      President; Secretary and Director
                  Since
      December 2006
 
 Background
of Directors and Executive Officers:
 
 P. Morgan
McCune.
 AA Degree
Dallas Art Institute, Multimedia, Animation, Web Design, Web Developer, Graphic
Artist, Medical Illustrator 6 years experience, Co-developer NextGen Orthopedic
DB Developer NextGen Physical Therapy DB, Medical Illustrator for NextGen EMR,
Development Proficiency: SQL 2005, Visual Studio 2005, .NET, C#,
VB.
 
 The
Registrant has one shareholder, the President, P. Morgan McCune, who owns at
least ten percent of the Company’s common stock. The initial Form 3 required to
be filed by the shareholder was filed late. P. Morgan McCune was not required to
file a Form 4 or Form 5 as his share holdings did not change.
 
 
 ITEM
11.                      EXECUTIVE
COMPENSATION
 
 Our sole
officer and director received the following compensation for the years of 2004
and 2005. He has no employment contract with the company.
  Name
      of Person
                  Receiving
      compensation
                
                Capacity
      in which he served
                  to
      receive remuneration
                
                Aggregate
                  remunerationP.
      Morgan McCune
                
                President,
      Secretary and Treasurer
                
                2007
      - $72,000
                  2006
      - $0
    
 As of the
date of this offering, our sole officer is our only employee. We have no
employment agreements with any officer, director or employee.
 
 
 ITEM
12.      SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
 
 The following table lists the officers,
directors and stockholders who, at the date hereof, own of record or
beneficially, directly or indirectly, more than 10% of the outstanding common
stock, and all officers and directors of the company:
    20
 
       Title/relationship
      to Issuer
                
                Name
      of Owner
                
                Amount
                  Owned
                  Before
      The Offering
                
                PercentPresident,
      Secretary and Director
                
                P.
      Morgan McCune
                
                13,000,000
                
                94.59%All
      officers and Directors as a group
                
                
                
                13,000,000
                
                94.59%
 
 
 No
options, warrants or rights have been issued by the Company.
 
   21
  PART
III
 ITEM
13.- Exhibits and Reports on Form 8-K
  (a)
                Exhibits
 No.
                Description31.1
                Certification
      of the Company’s Principal Executive Officer pursuant to Section 302 of
      the Sarbanes-Oxley Act of 200231.2
                Certification
      of the Company’s Principal Financial Officer pursuant to Section 302 of
      the Sarbanes-Oxley Act of 200232.1
                Certification
      of the Company’s Principal Executive Officer and Principal Financial
      Officer pursuant to 18 U.S.C. Section 1350, as adopted to Section 906 of
      the Sarbanes-Oxley Act of 2002.
 ITEM
14.                      PRINCIPAL
ACCOUNTING FEES AND SERVICES
 
 (1) Audit
fees
  The
aggregate fees billed for professional services rendered by our auditors, for
the audit of the registrant's annual financial statements and review of the
financial statements included in the registrant's Form 10-K or services that are
normally provided by the accountant in connection with statutory and regulatory
filings or engagements for fiscal years 2007, the first year of audit, was
$15,163.
  (2)
Audit-related fees
  None
  (3) Tax
fees
  None
  (4) All
other fees
  None
  (5) Audit
committee policies and procedures
  The
Company does not have an audit committee.
  (6) If
greater than 50 percent, disclose the percentage of hours expended on the
principal accountant's engagement to audit the registrant's financial statements
for the most recent fiscal year that were attributed to work performed by
persons other than the principal accountant's full-time, permanent
employees.
  Not
applicable.
 
 
 
   22
  PART
IV
 
 ITEM
15.                      EXHIBITS,
FINANCIAL STATEMENT SCHEDULES
 
 a)
1.           Financial Statements – Triple A
Medical, Inc. and Subsidiaries
 
 The
following are contained in this 2007 Form 10-K report:
 
 Report of
Independent Registered Public Accounting Firm
 
 Consolidated
Balance Sheets at December 31, 2007 and 2006
 
 Consolidated
Statements of Operations for the years ended December 31, 2007 and
2006
 
 Consolidated
Statements of Stockholders’ Equity for the years ended December 31, 2007 and
2006
 
 Consolidated
Statements of Cash Flows for the years ended December 31, 2007 and
2006
 
 Notes to
the Financial Statements
 
 
 a)
3.           Exhibits
 
 Exhibits
 
 Exhibit
Number                                                      Name
of Exhibit
 
 (a)
                Exhibits
 No.
                Description31.1
                Certification
      of the Company’s Principal Executive Officer pursuant to Section 302 of
      the Sarbanes-Oxley Act of 200231.2
                Certification
      of the Company’s Principal Financial Officer pursuant to Section 302 of
      the Sarbanes-Oxley Act of 200232.1
                Certification
      of the Company’s Principal Executive Officer and Principal Financial
      Officer pursuant to 18 U.S.C. Section 1350, as adopted to Section 906 of
      the Sarbanes-Oxley Act of 2002.
 
 
 
 
 
 
 
  23
  SIGNATURES
 
 Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this Report on Form 10-K to be signed on its behalf by the
undersigned, thereunto duly authorized.
 
 
 TRIPLE A
MEDICAL, INC.
 
 By:  /s/  P. Morgan
McCune
 P. Morgan
McCune
 Sole
Member of the Board of Directors
 
 Dated: October 21,
2008
 
 
 Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been
signed below by the following persons on behalf of the Registrant and in the
capacities and on the dates indicated.
 
 /s/  P. Morgan
McCune
 P. Morgan
McCune
 Sole
Member of the Board of Directors
 
 
 /s/  P. Morgan
McCune
 P. Morgan
McCune
 Chief
Executive Officer
 
 
 /s/  P. Morgan
McCune
 P. Morgan
McCune
 Chief
Financial Officer
 
 
 /s/  P. Morgan
McCune
 P. Morgan
McCune
 Chief
Accounting Officer
 
 Dated:
October 21, 2008
 
  24